2019
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal
Toma W, Kyte SL, Bagdas D, Jackson A, Meade JA, Rahman F, Chen ZJ, Del Fabbro E, Cantwell L, Kulkarni A, Thakur GA, Papke RL, Bigbee JW, Gewirtz DA, Damaj MI. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology 2019, 320: 113010. PMID: 31299179, PMCID: PMC6708482, DOI: 10.1016/j.expneurol.2019.113010.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNicotine rewardPaclitaxel treatmentRewarding effectsTreatment of CIPNPaclitaxel-induced mechanical hypersensitivityTumor-bearing NSG micePaclitaxel-induced peripheral neuropathyNon-small cell lung cancer cell linesCell lung cancer cell linesA549 non-small cell lung cancer cell lineMecamylamine-precipitated withdrawalAntitumor activityIntraepidermal nerve fibersLung cancer cell linesLung tumor growthNSCLC cell viabilityTumor-bearing miceIntrinsic rewarding effectsPlace preference testCancer cell linesConditioned place preference testMechanical hypersensitivityAgonist R
2018
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 2018, 138: 72-79. PMID: 29860196, PMCID: PMC6054891, DOI: 10.1016/j.neuropharm.2018.05.025.Peer-Reviewed Original ResearchConceptsEffects of vareniclineNicotine withdrawal signsNicotine rewardΑ5 nAChRWithdrawal signsHigh doseKnockout miceΒ2-nAChRsNicotine withdrawal-induced hyperalgesiaAdministration of vareniclineWithdrawal-induced hyperalgesiaΑ7 knockout miceDose-related mannerNicotinic acetylcholine receptorsΑ5 knockout micePlace preference testVarenicline doseCessation treatmentNicotine withdrawalSomatic signsVareniclineΑ7 nAChRsMouse modelCPP testNicotinic subtypes
2017
In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence
Jackson A, Bagdas D, Muldoon PP, Lichtman AH, Carroll FI, Greenwald M, Miles MF, Damaj MI. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Neuropharmacology 2017, 118: 38-45. PMID: 28279662, PMCID: PMC5410388, DOI: 10.1016/j.neuropharm.2017.03.005.Peer-Reviewed Original ResearchMeSH KeywordsAlpha7 Nicotinic Acetylcholine ReceptorAnesthetics, LocalAnimalsBenzamidesBridged Bicyclo CompoundsCocaineConditioning, OperantDisease Models, AnimalFenofibrateHypolipidemic AgentsMaleMiceMice, Inbred ICRNicotineNicotinic AgonistsOxazolesPPAR alphaPyrimidinesSelf AdministrationSubstance Withdrawal SyndromeTobacco Use DisorderTyrosineConceptsNicotine dependenceNicotinic acetylcholine receptorsNicotine rewardΑ7 nAChRsNicotine CPPWY-14643Acetylcholine receptorsRewarding propertiesNuclear peroxisome proliferator-activated receptorsΑ7 nicotinic acetylcholine receptorVentral tegmental area dopamine cellsEffect of α7Peroxisome proliferator-activated receptorNicotine withdrawal signsSmoking cessation therapyChronic tobacco useCurrent smoking cessation therapiesPPARα antagonist GW6471Main addictive componentPPARα-dependent mannerProliferator-activated receptorNicotine rewarding propertiesPlace preference testHomomeric α7 nAChRsSelf-administration model
2014
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Bagdas D, Muldoon P, Zhu A, Tyndale R, Damaj M. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85: 67-72. PMID: 24859605, PMCID: PMC4106981, DOI: 10.1016/j.neuropharm.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAryl Hydrocarbon HydroxylasesConditioning, PsychologicalCytochrome P450 Family 2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHyperalgesiaMaleMecamylamineMethoxsalenMice, Inbred ICRMotor ActivityNicotineNicotinic AgonistsNicotinic AntagonistsRewardSeverity of Illness IndexSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotine plasma levelsWithdrawal signsPlasma levelsAdministration of methoxsalenEffect of methoxsalenNicotine dependence behaviorsNicotine replacement therapyChronic nicotine infusionDependence-related behaviorsDrug elimination ratePlace preference testMetabolism of nicotineReward-like propertiesLack of enhancementSpontaneous withdrawalNicotine withdrawalReplacement therapyNicotine preferenceLow doseHigh doseNicotine infusionMouse CYP2A5CPP testActive nicotineNicotine levels